Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
- Pulmonary toxicities of gefitinib in patients with advanced non-small-cell lung cancer: a meta-analysis of randomized controlled trials.Medicine (Baltimore). 2016; 95: e3008
- FDA drug approval summary: gefitinib (ZD1839) (Iressa) tablets.Oncologist. 2003; 8: 303-306
- An official American Thoracic Society/European Respiratory Society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias.Am J Respir Crit Care Med. 2013; 188: 733-748
- Does KRAS mutational status predict chemoresistance in advanced non-small cell lung cancer (NSCLC)?.Lung Cancer. 2014; 83: 383-388
- Interstitial lung disease associated with drug therapy.Br J Cancer. 2004; 91: S18-S23
- AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer.N Engl J Med. 2015; 372: 1689-1699
- AZD9291-induced acute interstitial lung disease.Chin Med J. 2016; 129: 1507-1508
Disclosure: The authors declare no conflict of interest.